Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Tax Provisions (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Tax Provisions for 12 consecutive years, with $12.1 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 83.67% to $12.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.4 million through Dec 2025, up 98.34% year-over-year, with the annual reading at $23.4 million for FY2025, 98.24% up from the prior year.
  • Tax Provisions for Q4 2025 was $12.1 million at Theravance Biopharma, up from -$6.5 million in the prior quarter.
  • The five-year high for Tax Provisions was $18.4 million in Q2 2025, with the low at -$6.5 million in Q3 2025.
  • Average Tax Provisions over 5 years is $2.0 million, with a median of $375500.0 recorded in 2021.
  • The sharpest move saw Tax Provisions crashed 7142.86% in 2022, then surged 116566.67% in 2023.
  • Over 5 years, Tax Provisions stood at -$200000.0 in 2021, then soared by 98.5% to -$3000.0 in 2022, then soared by 116566.67% to $3.5 million in 2023, then surged by 88.55% to $6.6 million in 2024, then soared by 83.67% to $12.1 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $12.1 million, -$6.5 million, and $18.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.